UBS Group Analysts Give Novartis (NOVN) a CHF 80 Price Target
UBS Group set a CHF 80 price target on Novartis (VTX:NOVN) in a research report sent to investors on Thursday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.
NOVN has been the subject of several other reports. Barclays set a CHF 80 target price on Novartis and gave the company a sell rating in a research note on Thursday, January 25th. Kepler Capital Markets set a CHF 88 target price on Novartis and gave the company a buy rating in a research note on Friday, February 9th. Baader Bank set a CHF 95 target price on Novartis and gave the company a buy rating in a research note on Friday, February 16th. Bank of America set a CHF 87 target price on Novartis and gave the company a sell rating in a research note on Wednesday, December 6th. Finally, Morgan Stanley set a CHF 88 price target on Novartis and gave the company a buy rating in a research report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of CHF 88.88.
Novartis (VTX NOVN) opened at CHF 77.26 on Thursday. The company has a market capitalization of $201,600.00 and a P/E ratio of 25.00. Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.